BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 34690090)

  • 1. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Spira A; Zhou X; Chen L; Gnanasakthy A; Wang L; Ungar D; Curiel R; Liao L; Radford J; Kahl B
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):158-168. PubMed ID: 34690090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
    Caimi PF; Ai WZ; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Wang Y; Qin Y; Wang L; Xu ZC; Carlo-Stella C
    Haematologica; 2024 Apr; 109(4):1184-1193. PubMed ID: 37646659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine.
    Caimi PF; Hamadani M; Carlo-Stella C; Nickaeen M; Jordie E; Utsey K; Knab T; Zammarchi F; Cucchi D; Pantano S; Havenith K; Wang Y; Boni J
    EJHaem; 2024 Feb; 5(1):76-83. PubMed ID: 38406517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy.
    Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
    Haematologica; 2024 May; ():. PubMed ID: 38721745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.
    Phillips T; Lugtenburg P; Kalsekar A; Mutebi A; Wang A; Blaedel J; Kosa K; Martin S; Sacchi M; Kilavuz N; Thieblemont C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e78-e87.e2. PubMed ID: 38151388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
    Hamadani M; Spira A; Zhou X; Liao L; Chen L; Radford J; Ai W; Solh M; Ardeshna KM; Hess B; Caimi PF; Stathis A; Carlo-Stella C; Alderuccio JP; Kahl B; Wang Y; Qin Y; Xu ZC; Zinzani PL
    Blood Adv; 2024 Jan; 8(1):93-98. PubMed ID: 37871303
    [No Abstract]   [Full Text] [Related]  

  • 7. Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.
    Blood; 2024 Mar; 143(13):1316. PubMed ID: 38546633
    [No Abstract]   [Full Text] [Related]  

  • 8. Loncastuximab tesirine: Risk for dose variance.
    Kintzel PE
    Am J Health Syst Pharm; 2024 May; 81(11):e271-e273. PubMed ID: 38298157
    [No Abstract]   [Full Text] [Related]  

  • 9. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.
    Logue JM; Chavez JC
    Curr Treat Options Oncol; 2021 Oct; 22(12):112. PubMed ID: 34697650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.
    Furqan F; Hamadani M
    Ther Adv Hematol; 2022; 13():20406207221087511. PubMed ID: 35340719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
    Xu B
    Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.
    Aussedat G; Maucort-Boulch D; Rey P; Safar V; Karlin L; Elsensohn MH; Bachy E; Lebras L; Favier B; Vantard N; Ghergus D; Golfier C; Sesques P; Lazareth A; Lequeu H; Ferrant E; Salles G; Nicolas-Virelizier E; Ghesquieres H
    Leuk Lymphoma; 2022 Mar; 63(3):599-607. PubMed ID: 34720034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
    Duell J; Obr A; Augustin M; Endell J; Liu H; Geiger S; Silverman IM; Ambarkhane S; Rosenwald A
    Leuk Lymphoma; 2022 Feb; 63(2):468-472. PubMed ID: 34779360
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study.
    Cheng R; Scippa K; Locke FL; Snider JT; Jim H
    Oncol Ther; 2022 Jun; 10(1):123-141. PubMed ID: 34778941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
    Sehn LH; Hertzberg M; Opat S; Herrera AF; Assouline S; Flowers CR; Kim TM; McMillan A; Ozcan M; Safar V; Salles G; Ku G; Hirata J; Chang YM; Musick L; Matasar MJ
    Blood Adv; 2022 Jan; 6(2):533-543. PubMed ID: 34749395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
    Luminari S; Manni M; Galimberti S; Versari A; Tucci A; Boccomini C; Farina L; Olivieri J; Marcheselli L; Guerra L; Ferrero S; Arcaini L; Cavallo F; Kovalchuk S; Skrypets T; Del Giudice I; Chauvie S; Patti C; Stelitano C; Ricci F; Pinto A; Margiotta Casaluci G; Zilioli VR; Merli A; Ladetto M; Bolis S; Pavone V; Chiarenza A; Arcari A; Anastasia A; Dondi A; Mannina D; Federico M;
    J Clin Oncol; 2022 Mar; 40(7):729-739. PubMed ID: 34709880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
    Portell CA; Wages NA; Kahl BS; Budde LE; Chen RW; Cohen JB; Varhegyi NE; Petroni GR; Williams ME
    Blood Adv; 2022 Mar; 6(5):1490-1498. PubMed ID: 34700344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
    Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
    Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
    Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
    Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.